title: Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
abstract: BACKGROUND
  This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder (DSM-IV).
  
  
  METHODS
  Twenty individuals were enrolled in a 17-week, open-label trial of duloxetine at Massachusetts General Hospital. Data were collected between March 2007 and September 2012. Study measures assessing obsessive-compulsive disorder symptoms, quality of life, depression, and anxiety were administered at baseline and weeks 1, 5, 9, 13, and 17. The primary outcome measures were the Yale-Brown Obsessive Compulsive Scale and Clinical Global Improvement scale.
  
  
  RESULTS
  For the 12 study completers, pre- and posttreatment analyses revealed significant improvements (P<.05) on clinician- and self-rated measures of obsessive-compulsive disorder symptoms and quality of life. Among the 12 completers, more than one-half (n=7) satisfied full medication response criteria. Intention-to-treat analyses (n=20) showed similar improvements (P<.05) on primary and secondary study outcome measures.
  
  
  CONCLUSIONS
  The results of this study suggest that duloxetine may provide a significant reduction in symptoms for patients with obsessive-compulsive disorder. ClinicalTrials.gov NCT00464698; http://clinicaltrials.gov/ct2/show/NCT00464698?term=NCT00464698&rank=1.
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy). ddougherty@partners.org.
authors: Darin D
authors: DD
authors: Dougherty
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Andrew K
authors: AK
authors: Corse
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Tina
authors: T
authors: Chou
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Amanda
authors: A
authors: Duffy
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Amanda R
authors: AR
authors: Arulpragasam
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Thilo
authors: T
authors: Deckersbach
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Michael A
authors: MA
authors: Jenike
authors: Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA (Drs Dougherty, Corse, Chou, Duffy, Arulpragasam, and Deckersbach); OCD and Related Disorders Program, Massachusetts General Hospital, Boston, MA (Drs Dougherty, Jenike, and Keuthen); Department of Psychology, Harvard University, Cambridge, MA (Dr Chou); Department of Neuroscience, Brown University, Providence, RI (Dr Duffy).
authors: Nancy J
authors: NJ
authors: Keuthen
mesh_terms: D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000188:drug therapy / Q000503:physiopathology; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D000068736:Duloxetine Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D014179:Neurotransmitter Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014179:Neurotransmitter Uptake Inhibitors; D011619:Psychotropic Drugs; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
keywords: compulsions; duloxetine; obsessions; obsessive-compulsive disorder; serotonin-norepinephrine reuptake inhibitors
references: J Clin Psychopharmacol. 2003 Dec;23(6):568-75
references: 14624187
references: Arch Gen Psychiatry. 1961 Jun;4:561-71
references: 13688369
references: J Int Med Res. 1977;5 Suppl 5:42-8
references: 340306
references: Am J Psychiatry. 1987 Dec;144(12):1543-8
references: 3120604
references: J Consult Clin Psychol. 1988 Dec;56(6):893-7
references: 3204199
references: Arch Gen Psychiatry. 1989 Jan;46(1):36-44
references: 2491940
references: Arch Gen Psychiatry. 1989 Nov;46(11):1006-11
references: 2684084
references: Arch Gen Psychiatry. 1989 Nov;46(11):1012-6
references: 2510699
references: J Clin Psychopharmacol. 1990 Apr;10(2):152-3
references: 2341595
references: Am J Psychiatry. 1990 Jul;147(7):923-8
references: 2192564
references: Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Apr;24(2):68-70, 123
references: 1860383
references: Psychopharmacol Bull. 1993;29(2):321-6
references: 8290681
references: Am J Psychiatry. 1995 Dec;152(12):1832
references: 8526258
references: Am J Psychiatry. 1996 Apr;153(4):576-7
references: 8599411
references: Int Clin Psychopharmacol. 1996 Mar;11(1):21-9
references: 8732310
references: J Clin Psychopharmacol. 1996 Feb;16(1):81-4
references: 8834427
references: J Clin Psychopharmacol. 1999 Apr;19(2):172-6
references: 10211919
references: J Clin Psychol. 2004 Nov;60(11):1195-202
references: 15389617